Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer
- PMID: 29282893
- PMCID: PMC5806108
- DOI: 10.1002/cam4.1287
Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer
Abstract
In eukaryotic cells, autophagy is a process associated with programmed cell death. During this process, cytoplasmic proteins and organelles are engulfed by double-membrane autophagosomes, which then fuse with lysosomes to form autolysosomes. These autolysosomes then degrade their contents to recycle the cellular components. Autophagy has been implicated in a wide variety of physiological and pathological processes that are closely related to tumorigenesis. In recent years, an increasing number of studies have indicated that nonsteroidal anti-inflammatory drugs, such as celecoxib, meloxicam, sulindac, aspirin, sildenafil, rofecoxib, and sodium salicylate, have diverse effects in cancer that are mediated by the autophagy pathway. These nonsteroidal anti-inflammatory drugs can modulate tumor autophagy through the PI3K/Akt/mTOR, MAPK/ERK1/2, P53/DRAM, AMPK/mTOR, Bip/GRP78, CHOP/ GADD153, and HGF/MET signaling pathways and inhibit lysosome function, leading to p53-dependent G1 cell-cycle arrest. In this review, we summarize the research progress in autophagy induced by nonsteroidal anti-inflammatory drugs and the molecular mechanisms of autophagy in cancer cells to provide a reference for the potential benefits of nonsteroidal anti-inflammatory drugs in cancer chemotherapy.
Keywords: Autophagy; nonsteroidal anti-inflammatory drugs; programmed cell death.
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Figures




References
-
- Chiarugi, P. , and Giannoni E.. 2008. Anoikis: a necessary death program for anchorage‐dependent cells. Biochem. Pharmacol. 76:1352–1364. - PubMed
-
- Sato, K. , Tsuchihara K., Fujii S., Sugiyama M., Goya T., Atomi Y., et al. 2007. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 67:9677–9684. - PubMed
-
- Hour, T. C. , Chen J., Huang C. Y., Guan J. Y., Lu S. H., Hsieh C. Y., et al. 2000. Characterization of chemoresistance mechanisms in a series of cisplatin‐resistant transitional carcinoma cell lines. Anticancer Res. 20:3221–3225. - PubMed
-
- Yu, H. J. , Tsai T. C., Hsieh T. S., Chiu T. Y.. 1992. Characterization of a newly established human bladder carcinoma cell line, NTUB1. J. Formos. Med. Assoc. 91:608–613. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous